Analyst
Equibles does not estimate personal net worth.
Jay Bradner has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Amgen Inc on September 15, 2026. The companies whose calls Jay Bradner spoke on are classified in the Healthcare sector.
“DAZO DALIBEP is a CD40 ligand-targeted complex biotherapeutic that we're developing presently in lead indication of Sjogren's disease. This is an area of huge unmet need.”
“Starting with cardiovascular disease, where Amgen is a global leader in developing medicines that target remaining, often genetically defined, cardiometabolic risk factors that anchors our cardiovascular efforts as the only PCSK9 targeting therapy with outcomes data in both primary, and secondary prevention, supported…”
“Fourth quarter capped off a year of strong, disciplined execution across R&D. Throughout 2025, we advanced multiple late-stage programs, delivered five key regulatory approvals, and strengthened the evidence base supporting our marketed medicines.”
AMGN
Drug Manufacturers - General · Healthcare
